Impact of free curcumin and curcumin nanocapsules on viability and oxidative status of neural cell lines

Bianca Fagan Bissacottia, Priscila Marquezan Copetti, Nathieli Bianchin Bottaria, Samanta da Silva Gündel, Alencar Kolinski Machado, Michele Rorato Sagrillo, Aline Ferreira Ourique, Vera Maria Melchiors Morsch, and Aleksandro Schafer da Silvaa,c

Department of Biochemistry and Molecular Biology, Federal University of Santa Maria (UFSM), Santa Maria, Brazil; bGraduate Program in Nanosciences, Franciscan University (UFN), Santa Maria, Brazil; cGraduate Program of Animal Science, Universidade do Estado de Santa Catarina, Chapecó, Brazil

ABSTRACT
Curcumin is an active polyphenol substance found in the highest concentrations in the roots of Curcuma longa. Its health benefits have led to recent increases in the consumption of curcumin. It has anti-inflammatory and antioxidant activities and is a potent neuroprotective against diseases of the brain. Nevertheless, its low bioavailability and its relative difficulty crossing the blood-brain barrier limit curcumin’s use for these purposes. Curcumin-loaded nanoparticles may be an effective treatment for several diseases although there is a paucity of studies reporting its safety in the central nervous system (CNS). Therefore, this study aimed to identify non-neurotoxic concentrations of free curcumin and two nanoformulations of curcumin. Cell lines BV-2 and SH-SY5Y, both originating from the CNS, were evaluated after 24, 48, and 72 h of treatment with free curcumin and nanocapsules. We measured viability, proliferation, and dsDNA levels. We measured levels of reactive oxygen species and nitric oxide as proxies for oxidative stress in culture supernatants. We found that free curcumin was toxic at 10 and 20 μM, principally at 72 h. Nanoformulations were more neurotoxic than the free form. Safe concentrations of free curcumin are between 1–5 μM, and these concentrations were lower for nanoformulations. We determined the ideal concentrations of free curcumin and nanocapsules serving as a basis for studies of injuries that affect the CNS.

1. Introduction
Natural products are increasingly studied for the treatment of diseases. Curcumin is the primary active compound present in the roots of the Curcuma longa plant. This polyphenol has anti-inflammatory, antioxidant, antimicrobial, and anticarcinogenic properties (Ayati et al. 2019, Khazdair et al. 2019, Tomeh et al. 2019, Willenbacher et al. 2019).

Curcumin may prevent or treat diseases characterized by inflammation or oxidative stress; it scavenges reactive oxygen species (ROS) chelates metal ions and inhibits the mitogen-activating protein kinases pathway (Camacho-Barquero et al. 2007, Hewlings and Kalman 2017, Ayati et al. 2019).

Many reviews discussed the use of curcumin to treat diseases of the central nervous system (CNS), including Parkinson’s, Alzheimer’s, Huntington’s disease, and multiple sclerosis (Maiti and Dunbar 2018, Bhat et al. 2019, da Costa et al. 2019, Khazdair et al. 2019, Bagheri et al. 2020). In an in vitro experimental model of neurodegenerative disease, Armagan and Naziroglu (Armagan and Naziroğlu 2021) reported the neuroprotective action of curcumin by modulating oxidative stress. In addition, this polyphenol is capable to decrease neurotoxicity, which is proven by other models of neurological disorders in vitro (Fan et al. 2018, Wang et al. 2020, Armagan and Naziroğlu 2021, Wei et al. 2021, Xiang et al. 2021) and in vivo studies (Khan et al. 2019, Namgyal et al. 2020).

Despite its substantial benefits, curcumin is toxic in high doses, at which it becomes an oxidant. The use of curcumin is also limited by low bioavailability, which results from its rapid metabolism and elimination (Ahmed et al. 2012, Rakotoarisoa and Angelova 2018, Del Prado-Audelo et al. 2019, Vaiserman et al. 2020). Nanotechnology might overcome these limitations.

Pharmaceutical nanotechnology has been assisting researchers in developing pharmacological investigations, because nanostructures control the release of the active compound, consequently reducing toxicity and prolonging the therapeutic effect. Their characteristic size permits nanostructures to cross barriers, including the blood–brain barrier, for example, increasing bioavailability at diseased sites (Ahmed et al. 2018, Xiang et al. 2021). Curcumin-loaded nanoparticles may be an effective treatment for neurological disorders because nanostructures control the release of the active compound, consequently reducing toxicity and prolonging the therapeutic effect.

CONTACT Bianca Fagan Bissacotti (bianca_fibissacotti@hotmail.com); Aleksandro Schafer da Silva (aleksandro_ss@yahoo.com.br); Department of Biochemistry and Molecular Biology, Federal University of Santa Maria (UFSM), Avenida Roraima, No. 1000, Camobi District, Santa Maria 97105900, Brazil

* Bianca Fagan Bissacotti and Priscila Marquezan Copetti are co-first authors and contributed equally to this work.

© 2021 Informa UK Limited, trading as Taylor & Francis Group
et al. 2012, Rakotoarisoa and Angelova 2018, Sadegh Malvajerdi et al. 2019).

Some studies demonstrated curcumin nanoformulations in the treatment of CNS diseases (Azami et al. 2018, Mursaleen et al. 2020). In a study comparing free curcumin and its nanostructured form to reverse hippocampal damage in rats, a curcumin nanocomposite was superior to curcumin alone (Zaki et al. 2020).

Curcumin and its nanoformulations possess several positive biological activities; however, few studies reported its safe concentrations in normal CNS cells. Such an evaluation is essential to determine safe concentrations of these agents that would permit further study (Qureshi et al. 1992, Soleimani et al. 2018, Ghasemi et al. 2019).

Therefore, the objective of the present study was to determine nontoxic concentrations of free curcumin and two types of nanoformulations containing curcumin using cell lines derived from the CNS.

2. Materials and methods

2.1. Nanocapsules preparation

Nanocapsules were developed using interfacial deposition of the preformed polymer, following the descriptions described by Jaguezeski et al. (2019), with two polymers, poly-ε-caprolactone (PCL) (Sigma-Aldrich) or Eudragit L-100 (EDG) (Evonik).

In both formulations, the oil phase was poured into the aqueous phase and stirred for 15 min. The organic solvent was evaporated using a rotary evaporator. The PCL nanocapsule (NC-PCL) was developed containing 2 mg/mL of curcumin (Sigma-Aldrich), and the EDG nanocapsule (NC-EDG) was developed containing 0.25 mg/mL of curcumin (Sigma-Aldrich), and the EDG nanocapsule (NC-EDG) was developed containing 0.25 mg/mL of curcumin (Sigma-Aldrich), and the EDG nanocapsule (NC-EDG) was developed containing 0.25 mg/mL of curcumin (Sigma-Aldrich), and the EDG nanocapsule (NC-EDG) was developed containing 0.25 mg/mL of curcumin (Sigma-Aldrich), and the EDG nanocapsule (NC-EDG) was developed containing 0.25 mg/mL of curcumin (Sigma-Aldrich), and the EDG nanocapsule (NC-EDG) was developed containing 0.25 mg/mL of curcumin (Sigma-Aldrich), and the EDG nanocapsule (NC-EDG) was developed containing 0.25 mg/mL of curcumin (Sigma-Aldrich), and the EDG nanocapsule (NC-EDG) was developed containing 0.25 mg/mL of curcumin (Sigma-Aldrich), and the EDG nanocapsule (NC-EDG) was developed containing 0.25 mg/mL of curcumin (Sigma-Aldrich), and the EDG nanocapsule (NC-EDG) was developed containing 0.25 mg/mL of curcumin (Sigma-Aldrich), and the EDG nanocapsule (NC-EDG) was developed containing 0.25 mg/mL of curcumin (Sigma-Aldrich). Curcumin and its nanoformulations possess several positive biological activities; however, few studies reported its safe concentrations in normal CNS cells. Such an evaluation is essential to determine safe concentrations of these agents that would permit further study (Qureshi et al. 1992, Soleimani et al. 2018, Ghasemi et al. 2019).

Therefore, the objective of the present study was to determine nontoxic concentrations of free curcumin and two types of nanoformulations containing curcumin using cell lines derived from the CNS.

2.2. Nanocapsules characterization

We used the dynamic light scattering technique to determine the mean particle size and polydispersity index (Zetasizer® nano-ZS model ZEN 3600, Malvern). The zeta potential (ZP) was determined using the electrophoretic mobility technique (Zetasizer® nano – ZS model ZEN 3600, Malvern) and pH was determined directly using a potentiometer (DM-22, Digimed®) (Gündel et al. 2018).

The curcumin content in the nanocapsules was determined using high-performance liquid chromatography (HPLC). The encapsulation efficiency was determined using ultrafiltration-centrifugation with subsequent HPLC analysis according to the methodology described by Jaguezeski et al. (2019).

2.3. Cell culture

Microglia cells (cell line BV-2) and neuron-like cells (cell line SH-SY5Y) were obtained from the Rio de Janeiro Cell Bank (ATCC® 0356, RJ, Brazil; ATCC® 0223, RJ, Brazil, respectively). BV-2 were cultured in RPMI-1640 medium (Sigma-Aldrich) containing 10 mM HEPES (Sigma-Aldrich), 10% of fetal bovine serum (FBS) (Gibco® Thermo Fisher) and supplemented with 1% of antibiotic (100 U/mL penicillin; 100 mg/mL streptomycin) (Gibco® Thermo Fisher). SH-SY5Y cells were cultured in Dulbecco’s Modified Eagle Medium containing F12 supplement (Gibco® Thermo Fisher) with 10% FBS and 1% antibiotic. Cells were cultured at 37°C with 95% oxygen and 5% CO2 until the numbers of cells were sufficient to perform the experimental treatments and analyses.

2.4. Treatments

BV-2 and SH-SY5Y cells were seeded in 96-well plates at 2.5 × 10^5 cells/mL. The neurotoxicities of free curcumin, NC-EDG, and NC-PCL were tested using a concentration-response curve (0.01–20 μM) applied to both line cells at 24, 48, 72 h of exposure. For positive control, we used 25 μM hydrogen peroxide (H₂O₂) and negative control (CTL) only cells. We also used 1% ethanol as a control because curcumin was first diluted in this solvent. After the periods of incubation, cells were subjected to colorimetric and fluorometric assays.

2.5. Mitochondrial viability

Mitochondrial viability was measured using the MTT assay to measure cell viability or proliferative status. Cells were incubated with MTT reagent (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) (Sigma-Aldrich) at 5 mg/mL for up to 2 h. Then, dimethylsulfoxide (Sigma-Aldrich) was added, and the absorbance was determined at 560 nm (Fukui et al. 2010).

2.6. Extracellular double-strand DNA quantification

Quantification of extracellular-double-strand DNA (dsDNA) was performed in the cellular supernatants using the Quant-IT PicoGreen® dsDNA kit (Thermo Fisher). The reagent was added to each sample for 5 min at room temperature, avoiding light exposure. Emitted fluorescence was measured at 480 nm of excitation and 520 nm of emission (Ahn et al. 1996).

2.7. Reactive oxygen species levels

The quantification of ROS production was conducted in supernatants using 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) reagent (Sigma-Aldrich). Fluorescence reading was performed at excitation of 485 nm and emission 520 nm after 1-h incubation with the reagent at room temperature and under light protection (Costa et al. 2012).

2.8. Nitric oxide levels

The determination of NO present in the culture supernatant was based on an indirect measurement protocol published by Choi et al., which uses Griess reagent to detect organic
nitrite. The absorbance was determined at 560 nm (Choi et al. 2012).

2.9. Statistical analysis

The results were transformed to percentages for the negative control group. Statistical differences between groups were analyzed using one-way ANOVA, followed by the Tukey test, using GraphPad Prism 8 software. The data were presented as mean±SEM. Values were considered statistically significant when p < 0.05.

3. Results

3.1. Nanocapsules characterization

The NC-PCL and NB-PCL formulations showed particle sizes of 194±0.31 nm and 188±1.10 nm, respectively. NC-EDG measured 168±1.96 nm, and NB-EDG were 169±1.08 nm in size. All formulations showed a polydispersion index of 0.1, indicating size uniformity. The nanocapsules gave negative ZP and acidic pH, characteristics of their constituents (NC-PCL: −8.16±0.53 mV; 6.23±0.02, NB-PCL: −7.25±0.67 mV; 6.35±0.03, NC-EDG: −17.00±1.04 mV; 4.35±0.02, NB-EDG: −17.53±1.30 mV; 4.33±0.02, respectively). The encapsulation efficiency of the nanoformulations was 100% in all cases, with curcumin concentrations of 0.25 mg/mL, for NC-EDG and 2 mg/mL for NC-PCL (Supplemental Table 1).

3.2. Curcumin treatments decrease or increase viability depending on the exposure time

To determine the viability of BV-2 cells against exposure of treatments with free and nanoencapsulated curcumin, the MTT assay demonstrated, that 20 μM of NB-EDG decreased microglial viability at 24 h, as did 0.01 and 20 μM NC-EDG. Treatment with NB-PCL showed no statistically significant difference; however, but 0.05, 0.5, and 1.0 μM of NC-PCL stimulated proliferation (Figure 1(A)).

After 48 h of exposure to treatments, only 20 μM of NB-EDG increased cell viability (Figure 1(B)). At 72 h, the three lowest concentrations of NB-EDG and NC-EDG (0.01, 0.05, and 0.1 μM) decreased cell viability in BV-2 cells (Figure 1(C)). By contrast, from 2.5 to 20 μM, NC-EDG increased cell viability (Figure 1(C)). Free curcumin showed no differences from the control group (Figure 1(A–C)).

SH-SY5Y cells are a subclone of neurons originating from human neuroblastoma. This cellular line is widely used for in vitro models of neural injuries, verifying the neurotoxicity of compounds and neuroprotection (Mursaleen et al. 2020, Armağan and Nazıroğlu 2021, Xiang et al. 2021).

The analysis of neuronal viability, over 24 h of exposure showed that 0.5, 1.0, 2.5, and 5 μM, as well as 2.5 and 5.0 μM of NB-EDG and NC-EDG, respectively, induced neuronal cell proliferation. On the contrary, was found in 0.01 μM of NBPCL (Figure 1(D)).

At 48 h, only 20 μM of free curcumin reduced cell viability (Figure 1(E)). When neuronal-like cells were incubated for 72 h, 0.5 and 1.0 μM NC-EDG increased cell viability (Figure 1(F)).

3.3. Curcumin nanocapsules induce membrane damage and DNA exposure

Impacts of curcumin on BV-2 and SH-SY5Y cells were determined at 24, 48 and, 72 h. Measurements of free dsDNA in the supernatants of BV-2 and SH-SY5Y cells are presented in Figure 2. In BV-2 cells, 0.01, 0.05, and 0.1 μM of NB-EDG and NC-EDG were associated with less dsDNA at 24 h, whereas the opposite occurred at the two highest concentrations (10 and 20 μM). At 0.05, 0.1, 0.5, and 1.0 μM, NC-PCL caused membrane damage, exposing the DNA in the supernatants (Figure 2(A)).

At 48 h, dsDNA content was lower than CTL, when 0.01, 0.05, and 0.1 μM of NB-EDG and NC-EDG were used in BV-2 cells. A considerable increase of free dsDNA in supernatants was observed when 2.5 until 20 μM of NB-EDG and NC-EDG were added into the cell medium. The same occurred with 0.01, 0.05, 0.1, and 1.0 μM of NC-PCL. The free curcumin treatment was associated with a slight increase in free dsDNA at 1.0 and 2.5 μM after exposure to BV-2 cells (Figure 2(B)).

At 72 h after free curcumin or nanocapsules treatment of BV-2 cells, the dsDNA content in the supernatant showed increases for all nanoformulations (Figure 2(C)). No significant results of free curcumin were observed in BV-2 cells (Figure 2(C)). The amount of free dsDNA in the supernatants of neuronal-like cells increased in a concentration-dependent manner for EDG nanocapsules. Concentrations of 0.1, 0.5, 10, and 20 μM of NC-PCL also increased levels of dsDNA at 24 h (Figure 2(D)). At 48 h after exposure, the same occurred for nanoformulations with EDG. Nanocapsules with PCL also increased dsDNA content for all concentrations (Figure 2(E)). At longer exposure times, dsDNA levels supernatants significantly increased with treatment of 20 μM free curcumin, 1.0 to 20 μM of NB-EDG, 0.5 μM of NC-EDG and all concentrations of PCL nanocapsules (Figure 2(F)).

3.4. Curcumin nanocapsules modulated NO release in BV-2 and SH-SY5Y cells

The BV-2 cell line originates from the microglia of C57BL/6 mouse brain tissue. We have used these cells because of their phagocytosis activity and involvement in neuroinflammation in the brain (Ghasemi et al. 2019). To measure the effects of free curcumin and nanocapsules as a NO modulator, nitrite/nitrate levels were measured (Figure 3).

The highest concentration of both curcumin nanocapsules (20 μM) increased levels of NO in BV-2 cells at 24 h (Figure 3(A)). After 48 and 72 h, only nanocapsules with EDG maintained the increase (Figure 3(B,C)). In neuronal-like cells, NO levels were significantly increased in the 20 μM treatments of NB-EDG and NC-EDG at all exposure times (Figure 3(D–F)).
Figure 1. Cellular viability or proliferative status using MTT assay. (A) BV-2 cells after 24 h of exposure to curcumin treatments. (B) BV-2 cells after 48 h of exposure to curcumin treatments. (C) BV-2 cells after 72 h of exposure to curcumin treatments. (D) SH-SYSY cells after 24 h of exposure to curcumin treatments. (E) SH-SYSY cells after 48 h of exposure to curcumin treatments. (F) SH-SYSY cells after 72 h of exposure to curcumin treatments. NB-EDG: nanocapsule of EDG without curcumin; NC-EDG: nanocapsule of EDG with curcumin; NB-PCL: nanocapsule of PCL without curcumin; NC-PCL: nanocapsule of PCL with curcumin; Curcumin: free curcumin; CTL: negative control. Statistical analysis was performed comparing treatment groups with the negative control. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Figure 2. Membrane damage and DNA exposure using the PicoGreen assay. (a) BV-2 cells after 24 h of exposure to curcumin treatments. (b) BV-2 cells after 48 h of exposure to curcumin treatments. (c) BV-2 cells after 72 h of exposure to curcumin treatments. (d) SH-SYSY cells after 24 h of exposure to curcumin treatments. (e) SH-SYSY cells after 48 h of exposure to curcumin treatments. (f) SH-SYSY cells after 72 h of exposure to curcumin treatments. NB-EDG: nanocapsule of EDG without curcumin; NC-EDG: nanocapsule of EDG with curcumin; NB-PCL: nanocapsule of PCL without curcumin; NC-PCL: nanocapsule of PCL with curcumin; Curcumin: free curcumin; CTL: negative control. Statistical analysis was performed comparing treatment groups with the negative control. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Figure 3. NO levels in supernatants using Griess reagent. (A) BV-2 cells after 24 h of exposure to curcumin treatments. (B) BV-2 cells after 48 h of exposure to curcumin treatments. (C) BV-2 cells after 72 h of exposure to curcumin treatments. (D) SH-SYSY cells after 24 h of exposure to curcumin treatments. (E) SH-SYSY cells after 48 h of exposure to curcumin treatments. (F) SH-SYSY cells after 72 h of exposure to curcumin treatments. NB-EDG: nanocapsule of EDG without curcumin; NC-EDG: nanocapsule of EDG with curcumin; NB-PCL: nanocapsule of PCL without curcumin; NC-PCL: nanocapsule of PCL with curcumin; Curcumin: free curcumin; CTL: negative control. Statistical analysis was performed comparing treatment groups with the negative control. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
3.5. Modulatory effects of curcumin nanocapsules on ROS levels

Several studies reported the anti-oxidant effects of curcumin. Here, we sought to determine the optimal concentration to avoid ROS generation in BV2 and SH-SY5Y cells. We found lower ROS levels 24 h after application of free curcumin (10 and 20 μM), NB-EDG (0.01 up to 5.0 μM), NC-EDG (0.01 up to 20 μM), NB-PCL (0.01, 0.05, 0.5, 1.0 and 5.0 μM), and NC-PCL (0.01 μM and 0.5 up to 20 μM) in BV-2 cells than in CTL (Figure 4(A)).

At 48 h after nanocapsules treatments, ROS levels increased when NB-EDG (10 and 20 μM), NB-PLC (1.0, 2.5, and 20 μM), or NC-PCL (0.05 and 0.1 μM) were used when compared to CTL (Figure 4(B)). In contrast, high-concentration free curcumin (20 μM) gave lower ROS levels than CTL in BV-2 cells (Figure 4(B)).

At the end of the experiment, the addition of free curcumin (0.05 μM), NB-EDG (0.1, 0.5, 2.5, and 10 μM) gave higher ROS levels than CTL in BV-2 cells (Figure 4(C)). By contrast, free curcumin (20 μM), NB-PCL (0.01 up to 10 μM), and NC-PCL (0.01 up to 20 μM) significantly diminished ROS levels in BV-2 cells compared to the CTL (Figure 4(C)).

In SH-SY5Y cells, ROS production also increased for all nanocapsule preparations; curcumin groups showed no significant changes after 24 h (Figure 4(D)). Our results demonstrate decreased ROS levels according to the concentration of NC-EDG (from 1.0 μM. The same happened when the cells were exposed to NC-PCL for 48 h. From 5 μM of curcumin, ROS levels also decreased (Figure 4(E)). The two curcumin nanofomulations decreased ROS production from the 2.5 μM concentration and 10 and 20 μM of free curcumin; however, only 0.01 μM of free curcumin was associated with increased ROS production (Figure 4(F)).

4. Discussion

Screening of natural compounds is critically important because they are increasingly used to prevent morbidities without proper monitoring (Parasuraman 2011). In particular, curcumin has many beneficial effects; however, its low bioavailability and rapid metabolism suggest the need for nanoformulations (Umerska et al. 2018, Del Prado-Audelo et al. 2019).

In the present study, two curcumin nanocapsules were prepared, NC-EDG and NC-PCL. We also prepared two nanoformulations without curcumin to serve as controls. The physio-chemical characteristics of both curcumin nanocapsules showed an efficiency of encapsulation and uniformity of nanometric size; these results were satisfactory according to the production protocol established by our research group (Gündel et al. 2018, Jaguezeski et al. 2019). Furthermore, nanoformulations have acid pH, but they are beforehand diluted in the culture medium (pH 7.2–7.4) to be added with the cells, therefore, pH values of the treatments become physiological. Nanoformulations with acid pH, after contact with the culture medium, independent of the type and incubation time, pH values are increased to physiological, not harming the cells and the in vitro tests (Gündel et al. 2018, Dalcin et al. 2019, Copetti et al. 2020). The pH did not influence the results of this research.

Curcumin has been considered a promising approach to the treatment of several brain disorders. We determined cytotoxicity parameters of free curcumin and curcumin-loaded nanocapsules measured as cell death, proliferation, and oxidative profile. In vitro experimental models are useful tools because they provide preliminary profiles of cellular responses and possible damages that could occur, guiding subsequent studies (Eisenbrand et al. 2002, Gartlon et al. 2006).

A review by Soleimani, Sahebkar, and Hosseinazadeh discussed the safety and toxicity of curcumin in in vitro and in vivo models, both in animal and human trials (Soleimani et al. 2018). According to the authors, curcumin was nontoxic up to specific concentrations, depending on the model studied. Nevertheless, the use of curcumin nanoformulations needs to be explored in more depth. The authors indicated that curcumin is non-mutagenic and safe for pregnant animals; however, this assertion should be tested carefully (Soleimani et al. 2018). In agreement, some authors defended the notion that nanocapsulated medications should be tested for their safety. We evaluated NC-PCL and NC-EDG and free curcumin in microglial and neuronal-like cell lines at different incubation periods.

In BV-2 cells, at 24 h after exposure, we found that free curcumin at the two highest concentrations decreased ROS production and 0.5–2.5 μM of NC-EDG and 2.5 and 5 μM for NC-PCL were safe to use in vitro, in that they did not compromise cell homeostasis. However, at 48 h of exposure, specific concentrations of the nanoformulations unbalanced the oxidative profile. The amount of free DNA increased, suggesting that the nontoxic concentrations were 0.5–1.0 μM for NC-EDG and 2.5 μM for NC-PCL, in this situation. With longer exposure times, the amount of free dsDNA was highly significant for all nanoformulations, suggesting possible membrane damage; this finding can be explained by the interaction of the polymers that make up the nanocapsule with the cell membrane, increasing permeability (Umerska et al. 2018, Ziešanka et al. 2020). By contrast, curcumin alone did not cause membrane damage at 72 h.

Exposure of these agents to neuronal-like cells showed that curcumin nanocapsules were associated with increased ROS levels, suggesting oxidative stress. NC-EDG was associated with high dsDNA levels at all concentrations, suggesting membrane damage, possibly due to EDG interacting with the cell membrane. At 48 h, the amount of free dsDNA also increased. By contrast, from 1.0 μM of nanofomulations, ROS production decreased, suggesting that perhaps the nanocapsules positively modulated oxidative mechanism. Curcumin was safe up to 10 μM; however, it was associated with ROS levels from 2.5 μM. At 72 h, the changes were more significant, suggesting compromised cellular homeostasis.

The antioxidant properties of curcumin are among the essential features that raise its therapeutic value. Severe oxidative stress is a cause of neural loss in the context of brain disorders (Hewlings and Kalman 2017). The production of ROS and NO, under conditions of homeostasis, occurs as part of cellular physiological metabolism and is essential for the
Figure 4. ROS levels in supernatants using DCFH-DA reagent. (A) BV-2 cells after 24 h of exposure to curcumin treatments. (B) BV-2 cells after 48 h of exposure to curcumin treatments. (C) BV-2 cells after 72 h of exposure to curcumin treatments. (D) SH-SY5Y cells after 24 h of exposure to curcumin treatments. (E) SH-SY5Y cells after 48 h of exposure to curcumin treatments. (F) SH-SY5Y cells after 72 h of exposure to curcumin treatments. NB-EDG: nanocapsule of EDG without curcumin; NC-EDG: nanocapsule of EDG with curcumin; NB-PCL: nanocapsule of PCL without curcumin; NC-PCL: nanocapsule of PCL with curcumin; Curcumin: free curcumin; CTL: negative control. Statistical analysis was performed comparing treatment groups with the negative control.

\[ p < 0.05; \quad \star \quad p < 0.01; \quad \star \star \star \quad p < 0.001; \quad \star \star \star \star \quad p < 0.0001. \]
organism to identify and eliminate stressors agent. Decreased ROS levels can be harmful under normal conditions but not during diseases treatment. The mechanisms by which curcumin decrease ROS levels, unbalancing the compromising antioxidant profile, involve its antioxidant activity, which neutralizes ROS formed by cells (Camacho-Barquero et al. 2007, Hewlings and Kalman 2017, Ayati et al. 2019, Tomeh et al. 2019, Liczbiński et al. 2020). Studies showed that cancer cells are more susceptible to curcumin than normal cells; curcumin’s mechanism of action involves the regulation of ROS production, depending on cell type and experimental conditions (Fujisawa et al. 2004, Barzegar and Moosavi-Movahedi 2011, Nakamae et al. 2019, Liczbiński et al. 2020).

Here, we demonstrated that 10 and 20 μM of curcumin, depending on the exposure time, were harmful to cells, causing lower cell viability. In contrast, intermediate curcumin concentrations showed less neurotoxicity compared to the same concentrations of nanoformulations, as these obtained more significant statistical results when compared with negative control. This can be explained by the fact that nanoformulations have components that generate cytotoxicity, including the surfactant polysorbate 80. This fact also explains decreased or increased cell viability, membrane damage, and imbalance in levels of ROS and NO in nanoformulations that did not contain curcumin, used here as controls (Zielnińska et al. 2020).

Comparing the two curcumin nanoformulations, NC-PCL showed better results than NC-EDG, indicated by the lower significance levels when compared to negative control; however, the optimal choice for use in subsequent experiments will depend on the investigation experimental design because NC-PCL is more suitable for parenteral administration and NC-EDG is better for the oral route; this is because the constituent polymers differ for each nanocapsule. It is also important to highlight that in vitro screening tests are very important; however, results obtained in vivo may present different results, due to the consideration of an organism and its metabolism as a whole (Ahmed et al. 2012, Umerska et al. 2018).

It is important to note that cellular behavior, oxidative status depend on the exposure time. Damage increased over time primarily due to the high levels of free DNA in the supernatants in BV-2 cells and high levels of NO for 20 μM of NC-EDG. These characteristics must be considered when formulating the experimental design of a study.

No studies focused on safe concentration-response curves of curcumin in healthy cells originating from the CNS; few studies are the same in healthy cells from tissue sources (Syng-Ai et al. 2004, Bala et al. 2006, Kunwar et al. 2008, Balaji and Chempakam 2010, Ghasemi et al. 2019). However, in animals, the ethanolic extract of the rhizomes of C. longa, when administered chronically, changed the weight of the heart and lung (Qureshi et al. 1992). Corroborating this, Balaji and Chempakam demonstrated the toxicity of several components of C. longa, among them curcumin, with dose-dependent hepatotoxicity (Balaji and Chempakam 2010).

Cancer cell lines have been used to determine the ideal concentration of curcumin treatment and neural lines for brain injuries in vitro models. In the PC12 cancer cells, curcumin decreased cell viability in a concentration-dependent manner (Mendonça et al. 2009). Using microglial BV-2 cells, Zhang et al. found that curcumin inhibited lipopolysaccharide-induced neuroinflammation at 1, 5, 10, 20, and 40 μM (Zhang et al. 2019). Curcumin also inhibited oxidative stress by decreasing ROS in a model of neurodegenerative disease with SH-SYSY cells at 1, 2.5, and 5 μM (Xiang et al. 2021). Mursaleen et al. used curcumin nanoformulation 5 and 10 μM to protect the cells against neurotoxicity induced by rotenone in SH-SYSY cells (Mursaleen et al. 2020).

These studies demonstrate that our results for safe concentrations of curcumin are in line with those used to treat diseases that affect the CNS. Therefore, concentrations between 1.0 and 5 μM are not harmful to healthy cells, but the curcumin concentration and time exposure are factors to induce toxicity, mainly 10 and 20 μM of curcumin. Nevertheless, because of the disadvantages of the substance in free form, nanoformulations at the same concentrations or even lower than those mentioned may deliver more satisfactory results by controlling the release of curcumin and increasing its bioavailability, in addition to crossing the blood-brain barrier and reaching the sites of brain injuries (Rakotoarisoa and Angelova 2018, Del Prado-Audelo et al. 2019, Sadegh Malvajerd et al. 2020).

According to our introductory study, which determined the non-neurotoxic concentrations of curcumin nanoformulations and their free form, researchers can use our findings as a basis for choosing the optimal concentrations for their experimental models. It is essential to use safe concentrations to analyze the pharmacological potential of natural products. Because the present study has a basic character, more specific investigations and in vivo experimental models must be carried out to test our findings.

5. Conclusion
Curcumin nanoformulations using PCL and EDG in BV-2 and SH-SYSY cells were more toxic than free curcumin. We suggest that 1.0–5 μM of free curcumin and curcumin nanocapsules may be useful for treating or preventing diseases that affect the CNS, as they do not cause collateral damage to healthy cells.

Author contributions
BFB and PMC equally performed the experiments, data analysis, and manuscript draft. SSG and AFS produced and characterized the nanocapsules. AKM, MRS, VMM, NBB, and ASS revised the manuscript and funding reagents. All authors read and approved the publication of this manuscript.

Disclosure statement
The authors declare no conflicts of interest.
Funding
The present work was financially supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior CAPES/PROEX process no. 88887.372278/2019-00 and 88887.372294/2019-00.

ORCID
Blanca Fagan Bissacotti http://orcid.org/0000-0001-6672-2530
Priscila Marquezan Copetti http://orcid.org/0000-0003-1140-6236
Nathiel Bianchin Bottari http://orcid.org/0000-0003-0294-9650
Samanta da Silva Gündel http://orcid.org/0000-0003-4708-6801
Alencar Kolinski Machado http://orcid.org/0000-0003-2003-8420
Michele Rorato Saggriollo http://orcid.org/0000-0001-5659-159X
Aline Ferreira Ourique http://orcid.org/0000-0003-0828-774X
Vera Maria Melchior Morsch http://orcid.org/0000-0002-5381-4556
Aleksandro Schaefer da Silva http://orcid.org/0000-0002-9860-1933

References
Ahmed, K., et al., 2012. Nanoemulsion- and emulsion-based delivery systems for curcumin: encapsulation and release properties. Food Chemistry, 132 (2), 799–807.
Ahn, S., Costa, J., and Emanuel, J., 1996. PicoGreen quantitation of DNA: effective evaluation of samples pre- or post-PCR. Nucleic Acids Research, 24 (13), 2623–2625.
Armaghan, H.H. and Naz roglu, M., 2021. Curcumin attenuates hypoxia-induced oxidative neurotoxicity, apoptosis, calcium, and zinc ion influxes in a neuronal cell line: involvement of TRPM2 channel. Neurotoxicity Research, 39 (3), 618–633.
Ayati, Z., et al., 2019. Ethnobotany, phytochemistry and traditional uses of Curcuma spp. and pharmacological profile of two important species (C. longa and C. zedoaria): a review. Current Pharmaceutical Design, 25 (8), 871–935.
Azami, S.J., et al., 2018. Curcumin nanoemulsion as a novel chemical for the treatment of acute and chronic toxoplasmosis in mice. International Journal of Nanomedicine, 13, 7363–7374.
Bagheri, H., et al., 2020. Effects of curcumin on mitochondria in neurodegenerative diseases. BioFactors, 46 (1), 5–20.
Bala, K., Tripathy, B.C., and Sharma, D., 2006. Neuroprotective and anti-aging effects of curcumin in aged rat brain regions. Biogerontology, 7 (2), 81–89.
Balaji, S. and Chempakam, B., 2010. Toxicity prediction of compounds from turmeric (Curcuma longa L). Food and Chemical Toxicology, 48 (10), 2951–2959.
Barzegar, A. and Moosavi-Movahedi, A.A., 2011. Intracellular ROS protection efficiency and free radical-scavenging activity of curcumin. PLoS One, 6 (10), e26012.
Bhat, A., et al., 2019. Benefits of curcumin in brain disorders. BioFactors, 45 (5), 666–689.
Camacho-Barquero, L., et al., 2007. Curcumin, a Curcuma longa constituient, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. International Immunopharmacology, 7 (3), 333–342.
Choi, W., et al., 2012. The regulatory effect of veratric acid on NO production in LPS-stimulated RAW264.7 macrophage cells. Cellular Immunology, 280 (2), 164–170.
Copetti, P.M., et al., 2020. Development, characterisation, stability study and antieukleamic evaluation of nanoemulsions containing Astrocaryum aculeatum extract. Natural Product Research, 1–6.
Costa, F., et al., 2012. Influence of Val16Ala SOD2 polymorphism on the in-vitro effect of clomiphene citrate in oxidative metabolism. Reproductive Biomedicine Online, 24 (4), 474–481.
da Costa, I.M., et al., 2019. Supplementation with Curcuma longa reverses neurotoxic and behavioral damage in models of Alzheimer’s disease: a systematic review. Current Neuropharmacology, 17 (5), 406–421.
Dalci, A.J.F., et al., 2019. Nanoencapsulation of the flavonoid dihydromyricetin protects against the genotoxicity and cytotoxicity induced by cationic nanocapsules. Colloids and Surfaces, B, Biointerfaces, 173, 798–805.
Del Prado-Audelo, M.L., et al., 2019. Formulations of curcumin nanoparticles for brain diseases. Biomolecules, 9 (2), 56–28.
Eisenbrand, G., et al., 2002. Methods of in vitro toxicology. Food and Chemical Toxicology, 40 (2–3), 193–236.
Fan, C., et al., 2018. Neuroprotective effects of curcumin on IL-1β-induced neuronal apoptosis and depression-like behaviors caused by chronic stress in rats. Frontiers in Cellular Neuroscience, 12, 516–517.
Fujisawa, S., et al., 2004. Cytotoxicity, ROS-generation activity and radical-scavenging activity of curcumin and related compounds. Anticancer Research, 24 (2B), 563–569.
Fukui, M., Choi, H.J., and Zhu, B.T., 2010. Mechanism for the protective effect of resveratrol against oxidative stress-induced neuronal death. Free Radical Biology & Medicine, 49 (5), 800–813.
Garton, J., et al., 2006. Evaluation of a proposed in vitro test strategy using neuronal and non-neuronal cell systems for detecting neurotoxicity. Toxicology in Vitro, 20 (8), 1569–1581.
Ghasemi, F., et al., 2019. Effects of curcumin on microglial cells. Neurotoxicity Research, 36 (1), 12–26.
Gündel, S., et al., 2019. Evaluation of cytotoxicity, genotoxicity and eco-toxicity of nanoemulsions containing Mancozeb and Eugenol. Ecotoxicology and Environmental Safety, 169, 207–215.
Gündel, S.S., et al., 2018. Basal oil-nanoemulsions: development, cytotoxicity and evaluation of antioxidant and antimicrobial potential. Journal of Drug Delivery Science and Technology, 46, 378–383.
Hewlings, S. and Kalman, D., 2017. Curcumin: a review of its effects on human health. Foods, 6 (10), 92.
Jagiełezski, A.M., et al., 2019. Low-dose curcumin-loaded Eurolgat L100-nanocapsules in the diet of dairy sheep increases antioxidant levels and reduces lipid peroxidation in milk. Journal of Food Biochemistry, 43 (8), 1–14.
Khan, M.S., et al., 2019. Dietary supplementation of the antioxidant curcumin halts systemic LPS-induced neuroinflammation-associated neurodegeneration and memory/synaptic impairment via the JNK/NF-κB/Akt signaling pathway in adult rats. Oxidative Medicine and Cellular Longevity, 2019, 1–23.
Khazdair, M.R., et al., 2019. Neuroprotective potency of some spice herbs, a literature review. Journal of Traditional and Complementary Medicine, 9 (2), 98–105.
Kunwar, A., et al., 2008. Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. Biochimica et Biophysica Acta, 1780 (4), 673–679.
Liczbiński, P., Michalowicz, J., and Bukowska, B., 2020. Molecular mechanism of curcumin action in signaling pathways: review of the latest research. Phytotherapy Research, 34 (8), 1992–2005.
Maiti, P. and Dunbar, G., 2018. Use of curcumin, a natural polyphenol for targeting molecular pathways in treating age-related neurodegenerative diseases. International Journal of Molecular Sciences, 19 (6), 1637.
Mendonça, L.M., et al., 2009. Evaluation of the cytotoxicity and genotoxicity of curcumin in PC12 cells. Mutation Research, 675 (1–2), 29–34.
Mursaleen, S., Somavarapu, S., and Zariwala, M.G., 2020. Deferoxamine and curcumin loaded nanocarriers protect against rotenone-induced neurotoxicity, Journal of Parkinson’s Disease, 10 (1), 99–111.
Nakamie, L., et al., 2019. Curcumin derivatives verify the essentiality of ROS upregulation in tumor suppression. Molecules, 24 (22), 4067–4025.
Namgyl, D., et al., 2020. The neuroprotective effect of curcumin against Cd-induced neurotoxicity and hippocampal neurogenesis promotion through CREB-BDNF signaling pathway. Toxicology, 442, 152542.
Parasuraman, S., 2011. Toxicological screening. Journal of Pharmacology & Pharmacotherapeutics, 2 (2), 74–79.
Qureshi, S., Shah, A.H., and Ageel, A.M., 1992. Toxicity studies on Alpinia galanga and Curcuma longa. Planta Medica, 58 (2), 124–127.
Rakotoarisoa, M. and Angelova, A., 2018. Amphiphilic nanocarrier systems for curcumin delivery in neurodegenerative disorders. Medicines, 5 (4), 126.
Sadegh Malvajerd, S., et al., 2019. Brain delivery of curcumin using solid lipid nanoparticles and nanostructured lipid carriers: preparation, optimization, and pharmacokinetic evaluation. ACS Chemical Neuroscience, 10 (1), 728–739.

Soleimani, V., Sahebkar, A., and Hosseinzadeh, H., 2018. Turmeric (Curcuma longa) and its major constituent (curcumin) as nontoxic and safe substances: review. Phytotherapy Research, 32 (6), 985–995.

Syng-Ai, C., Kumari, A.L., and Khar, A., 2004. Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2. Molecular Cancer Therapeutics, 3 (9), 1101–1108.

Tomeh, M.A., Hadianamrei, R., and Zhao, X., 2019. A review of curcumin and its derivatives as anticancer agents. International Journal of Molecular Sciences, 20 (5), 1033.

Umerska, A., et al., 2018. Polymeric nanoparticles for increasing oral bioavailability of Curcumin. Antioxidants, 7 (4), 46.

Vaiserman, A., Koliada, A., and Lushchak, O., 2020. Neuroinflammation in pathogenesis of Alzheimer’s disease: phytochemicals as potential therapeutics. Mechanisms of Ageing and Development, 189, 111259.

Wang, Z., et al., 2020. A curcumin derivative activates TFEB and protects against parkinsonian neurotoxicity in vitro. International Journal of Molecular Sciences, 21 (4), 1515.

Wei, W., et al., 2021. Dichloroacetic acid-induced dysfunction in rat hippocampus and the protective effect of curcumin. Metabolic Brain Disease, 36 (4), 545–556.

Willenbacher, E., et al., 2019. Curcumin: new insights into an ancient ingredient against cancer. International Journal of Molecular Sciences, 20 (8), 1808–1813.

Xiang, B., et al., 2021. Curcumin ameliorates copper-induced neurotoxicity through inhibiting oxidative stress and mitochondrial apoptosis in SH-SYSY cells. Neurochemical Research, 46 (2), 367–378.

Zaki, S.M., et al., 2020. Nano-curcumin versus curcumin in amelioration of deltamethrin-induced hippocampal damage. Histochemistry and Cell Biology, 154 (2), 157–175.

Zhang, J., et al., 2019. Curcumin inhibits LPS-induced neuroinflammation by promoting microglial M2 polarization via TREM2/TLR4/NF-κB pathways in BV2 cells. Molecular Immunology, 116, 29–37.

Zieliriska, A., et al., 2020. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules, 25 (16), 3731.